Local treatment of hepatocellular carcinoma with oligometastases: a meta-analysis (Preprint)

Abstract

Although recent studies have shown favorable results after local treatment for oligometastases, the clinical decision of applying local treatment for oligometastatic hepatocellular carcinoma (HCC) remains controversial.

This meta-analysis aimed to investigate the benefits of local treatment for HCC oligometastases

Pubmed, Embase, Medline, and Cochrane library were searched for studies until May 1st, 2022. Clinical studies involving at least five cases of HCC oligometsatases treated with local modalities were included. The primary endpoint was overall survival (OS). The benefit of local treatment was assessed as the pooled odds ratio (OR) among comparative series, and the pooled OS percentile was calculated from all studies including patients treated with local treatment. Complications of grade ≥3 were assessed subjectively.

A total of 10 studies involving 527 patients were included. Radiotherapy and radiofrequency ablation (RFA) were mainly performed (six and five studies) as local modalities treating oligometastases. Pooled OR of comparative series favored the use of local treatment (4.664, 95% confidence interval [CI]: 2.5958.380, p <0.001, I2: ~0.0%). Including all cohorts with patients underwent local treatment, pooled rates of 1-year OS was 71.8% (95% CI: 59.0-81.9; I2=81.5%), and pooled 2-year OS was 43.3% (95% CI: 29.1-59.6; I2=85.4%). Except for temporal or pre-existing toxicities, grade ≤3 complications were reported less than 10% in most studies, although common toxicities include pneumothorax and hematologic deficiency after RFA and radiotherapy, respecThis systematic review supports the application of local treatment for treating HCC oligometastases.tively. Grade 5 toxicity has not yet been reported.

This systematic review supports the application of local treatment for treating HCC oligometastases.

PROSPERO (CRD42023392734)